ID
24377
Description
NCT00079911 Study ID 100181 Clinical Study ID HS2100181 Study Title: An International, Randomized, Double-Blind, Placebo-Controlled Study of Valaciclovir for the Suppression and Episodic Treatment of Genital HSV Infection in HIV-Infected Persons with CD4+ lymphocyte count <100 cells/mm3. Patient Level Data Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00079911 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 4 Study Recruitment Status: Terminated Generic Name: valaciclovir Trade Name: ZELITREX,Valtrex,RAPIVIR,Novirus Study Indication: Genital Herpes; HIV infection
Keywords
Versions (1)
- 7/30/17 7/30/17 -
Copyright Holder
GlaxoSmithKline
Uploaded on
July 30, 2017
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
GSK Valaciclovir for the Suppression and Episodic Treatment of Genital HSV Infection in HIV-Infected Persons STATUS OF TREATMENT BLIND NCT00079911
GSK Valaciclovir for the Suppression and Episodic Treatment of Genital HSV Infection in HIV-Infected Persons STATUS OF TREATMENT BLIND NCT00079911
Similar models
GSK Valaciclovir for the Suppression and Episodic Treatment of Genital HSV Infection in HIV-Infected Persons STATUS OF TREATMENT BLIND NCT00079911
C3897431 (UMLS CUI [1,2])
C3897431 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,3])
C0034656 (UMLS CUI [1,2])
C3897431 (UMLS CUI [1,3])
C0034656 (UMLS CUI [1,2])
C3897431 (UMLS CUI [1,3])